Loss of Integrin-Linked Kinase Sensitizes Breast Cancer to SRC Inhibitors.
Henry BeethamBillie G C GriffithOlga MurinaAlexander E P LoftusDavid A ParryCarolin TempsJayne CulleyMorwenna T MuirAsier Unciti-BrocetaAndrew H SimsAdam ByronValerie G BruntonPublished in: Cancer research (2022)
A CRISPR-Cas9 screen reveals that loss of integrin-linked kinase synergizes with SRC inhibition, providing a new opportunity for enhancing the clinical effectiveness of SRC inhibitors in breast cancer.